Design (Testphase)
Risk & Weakness
Pradeep Bonde: $ Breakout Bearish
115
Findings
July 21, 2026
last calculated
Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · showing the 25 strongest hits
Bonde's dollar breakdown (original Stockbee formula 'o−c ≥ 0.90'): the stock closes at least $0.90 below its opening price — sustained selling pressure across the whole trading day, measured in dollars. Minimum daily volume 100,000 shares, average volume (50 days) ≥ 100,000 as a liquidity filter. Opening price calculated from the prior close and the gap.
Global filters: 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); fundamentally healthy names (Piotroski ≥ 5 or Funda Rating ≥ +10) are excluded.
🔔 Watch scanner
Terms in This Scanner Explained
(18)
- ADR (Average Daily Range)
- The average daily swing of a stock in percent - measured over 10 or 30 trading days (columns "ADR 10D/30D"). An ADR of 5% means: on a normal day the gap between the intraday low and high runs about 5%. Traders look for movement - that is why stocks with an ADR under 1% are filtered out globally. Not to be confused with ADR meaning "American Depositary Receipt" (a US certificate for foreign shares) - here ADR always means the daily swing.
- AI Classification
- Our company-by-company assessment of the AI boom based on SEC filings (the last four quarterly 10-Q reports and two annual 10-K reports): "Sells AI" (AI is a revenue source), "Threatened" (AI is a concrete business risk), "Uses AI" (operational use), or "Neutral" (no material AI exposure). Every classification requires at least two direct quote citations - otherwise the column shows "-". Not a quality judgment or a buy recommendation; the full file is on the stock page, methodology at /stocks/ai-rating-methodology.
- Analysis (Full Company Analysis)
- If the Analysis column shows "Read," there is an in-depth Minnow Street company analysis for this stock: business model, scanner findings, quarterly results, evidence from SEC filings, plus opportunities and risks. One click opens it directly.
- Avg/Yr 3Y (Average Annual Return)
- The stock's average annual return over the past 3 years. Shows at a glance whether a stock delivers over the long run or just had a short hot streak.
- Breakout
- The price clears a level where it previously failed multiple times (top of a base, an old high) - ideally on clearly elevated volume. For many momentum strategies, the breakout is the actual buy signal.
- Earnings Date
- The date of the next quarterly earnings report. Price gaps in either direction are common around this date - that is why we color it red when it is 7 days away or less, and yellow when it is 14 days away or less: elevated risk for fresh positions.
- EPS (Earnings per Share)
- Quarterly earnings divided by the number of shares outstanding. The most important growth metric: if EPS rises strongly over several quarters, the company is earning more money per share.
- Free Cash Flow (FCF)
- Operating cash flow minus capital expenditures - the money left over for everything else (debt paydown, acquisitions, or buybacks). Consistently positive free cash flow is one of the most honest signs of a healthy business model.
- Funda Rating (Fundamental Rating A+ to F)
- Our proprietary fundamental rating from -100 to +100 with a school-grade rank from A+ to F. Every stock is scored against all others by percentile: growth in earnings and revenue, earnings surprises, analyst estimates, and quality criteria such as margins, cash flow, and balance-sheet strength. A/A+ are the fundamentally strongest stocks in the universe.
- Gap
- The stock opens well above or below the prior close - a gap appears on the chart. Gaps are caused by overnight news (earnings, contracts, studies) and show that the valuation has shifted abruptly.
- Liquidity
- How easily a stock can be bought and sold without moving the price - measured by (dollar) volume. Illiquid stocks have wide spreads and jerky prices; that is why almost every scanner applies a minimum liquidity filter.
- Market Capitalization (Mkt Cap)
- The market value of the company: share price x total shares outstanding, shown here in billions of dollars. Micro caps (< $0.3B) are small and volatile, mega caps (> $200B) are heavyweights. Our scanner universe is deliberately capped at $50B - we look for stocks with room to run.
- Net Margin
- How much of revenue is left as profit? Net income divided by revenue, in percent. A 20% margin means: out of every dollar of revenue, 20 cents is left as profit. Rising margins are a strong quality signal.
- Operating Cash Flow (OCF)
- The cash that actually flows into the company from day-to-day operations - without accounting effects such as depreciation. A company can report book profits while still burning cash; operating cash flow reveals that.
- Piotroski F-Score
- A balance-sheet health check developed by Joseph Piotroski: 9 yes/no criteria covering earnings, cash flow, leverage, and efficiency produce a score from 0 to 9. Scores of 7 or higher are considered financially very solid, scores under 3 a warning sign.
- Sector & Industry
- Two levels of industry classification: sector is broad (e.g., Technology), industry is narrow (e.g., Semiconductors). Many strategies watch industry strength, because strong stocks are almost always found in strong industries.
- Stage (Weinstein Stages 1-4)
- Stan Weinstein divides every price chart into four stages: Stage 1 = basing (sideways after a downtrend), Stage 2 = uptrend (the only buying stage), Stage 3 = topping, Stage 4 = downtrend (avoid, or short candidate). Measured against the 30-week line (150-day moving average) and its slope.
- Stress RS (Strength on Stress Days)
- A stress day is a day on which both the overall market and the stock's own sector fell at least 0.5%. Stress RS counts on how many of these days the stock still closed green (shown as "g/n" = green days out of n stress days) and turns that into a rating from 1 to 99. High values point to buyers stepping in even on weak days - often a sign of institutional accumulation.
Hit List
Filter ▾
Rating (traffic light)
Stage
Funda Rating
Piotroski
Columns ▾
This scanner's columns
Extra columns
Tip: clicking a column header sorts the table by that column; a second click flips the direction.
| Symbol | Earnings | Avg/Y 3Y | Stress RS | Stage | Funda Rating | Piotroski | MktCap | Industry | AI Rating | Deep Dive | Deep-Dive Report | Sector | Price | YTD | 6 Mo. | 1 Year | Off High | Price Target | RS | EPS Rating | ADR 10D | ADR 30D | Beta | P/E | P/E (f) | P/S | P/B | P/FCF | PEG | EV/EBITDA | EBIT Margin | Gross Margin | Net Margin | ROE | ROA | Debt/Eq | Equity Ratio | Sales +/Y | Div. Yield | Payout Ratio | Altman Z | Inst. % | Short % | Analysts |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics Inc. | 08/04 | +290 % | 79 7/22 | Stage 2 | D -37 | 2 of 9 | 8.0 | Biotechnology | – | — | — | Healthcare | 97.30 $ | +196.2 % | +172.8 % | +487.5 % | −13.1 % | +13.3 % | 99 | 1 | 7.6 % | 6.7 % | 3.02 | — | 0.0 | 87.9 | 15.0 | — | — | -8.0 | 0.0 % | — | 0.0 % | -31.1 % | -22.7 % | — | 87.8 % | -100.0 % | 0.0 % | 0.0 % | 9.5 | 93.2 % | 15.6 % | 1.1 (11) |
| PRAX Praxis Precision Medicines Inc | 08/03 | +177 % | 96 10/22 | Stage 2 | C +7 | 4 of 9 | 9.1 | Biotechnology | – | — | — | Healthcare | 304.40 $ | +3.6 % | +27.6 % | +642.1 % | −10.6 % | +88.8 % | 98 | 42 | 6.8 % | 7.0 % | 2.76 | — | 0.0 | — | 6.1 | — | — | -6.9 | 0.0 % | -3,809.4 % | 0.0 % | -35.3 % | -23.0 % | 0.00 | 96.6 % | -100.0 % | 0.0 % | 0.0 % | 31.8 | 116.8 % | 12.8 % | 1.2 (12) |
| DFTX Definium Therapeutics, Inc. | 07/30 | +332 % | — | Stage 2 | D -49 | 1 of 9 | 0.0 | Biotechnology | – | — | — | Healthcare | 42.80 $ | +170.2 % | +246.6 % | +534.0 % | −4.7 % | +24.7 % | 98 | 50 | 14.0 % | 8.8 % | 2.21 | — | 0.0 | — | 21.3 | — | — | 0.0 | 0.0 % | — | 0.0 % | -94.7 % | -35.7 % | — | 69.5 % | — | 0.0 % | 0.0 % | 1.4 | 65.6 % | 9.8 % | — |
| KOD Kodiak Sciences Inc | 08/12 | +137 % | 40 4/22 | Stage 2 | E -55 | 2 of 9 | 2.1 | Biotechnology | – | — | — | Healthcare | 40.90 $ | +32.5 % | +21.4 % | +891.7 % | −28.7 % | +83.8 % | 98 | 42 | 8.0 % | 7.7 % | 2.20 | — | 0.0 | — | — | — | — | -0.1 | 0.0 % | — | 0.0 % | -208.8 % | -49.1 % | — | 36.6 % | — | 0.0 % | 0.0 % | -15.7 | 99.6 % | 26.6 % | 2.3 (6) |
| RVMD Revolution Medicines Inc | 08/05 | +188 % | 38 4/22 | Stage 2 | D -18 | 1 of 9 | 37.1 | Biotechnology | – | — | — | Healthcare | 180.40 $ | +112.8 % | +137.2 % | +324.0 % | −3.4 % | +10.7 % | 97 | 42 | 4.8 % | 4.4 % | 1.38 | — | 0.0 | — | 25.8 | — | — | -9.7 | 0.0 % | -151,691.8 % | 0.0 % | -76.7 % | -37.5 % | 0.29 | 66.6 % | -100.0 % | 0.0 % | 0.0 % | 1.4 | 95.7 % | 6.1 % | 1.0 (12) |
| INBX Inhibrx Biosciences, Inc. | 08/12 | — | 55 5/22 | Stage 2 | D -37 | 2 of 9 | 1.5 | Biotechnology | Neutral | — | — | Healthcare | 84.10 $ | +17.6 % | +18.8 % | +553.4 % | −38.6 % | +191.2 % | 97 | 42 | 6.9 % | 7.5 % | 3.43 | — | 0.0 | 1,120.8 | 212.3 | — | — | 0.0 | — | -7,697.5 % | 0.0 % | -354.7 % | -36.1 % | -0.28 | — | +550.0 % | 0.0 % | 0.0 % | -1.0 | 83.1 % | 30.1 % | — |
| TWST Twist Bioscience Corp | 08/03 | +131 % | 54 5/22 | Stage 2 | D -16 | 4 of 9 | 6.0 | Diagnostics & Research | – | — | — | Healthcare | 87.50 $ | +168.0 % | +192.9 % | +158.6 % | −1.8 % | -23.3 % | 96 | 42 | 7.7 % | 7.8 % | 2.12 | — | 0.0 | 14.7 | 13.7 | — | — | -35.3 | -34.9 % | 52.1 % | -19.9 % | -18.2 % | -12.9 % | 0.21 | 67.3 % | +20.3 % | 0.0 % | 0.0 % | -0.1 | 123.8 % | 36.4 % | 1.3 (12) |
| DNTH Dianthus Therapeutics Inc. | 08/06 | +247 % | — | Stage 2 | D -26 | 4 of 9 | 0.0 | Biotechnology | – | — | — | Healthcare | 101.00 $ | +112.4 % | +121.7 % | +427.9 % | −5.1 % | +39.4 % | 96 | 50 | 5.9 % | 6.6 % | 0.09 | — | 0.0 | — | — | — | — | -7.3 | -10,050.3 % | 100.0 % | 0.0 % | -22.7 % | -15.0 % | — | 96.4 % | -67.4 % | 0.0 % | 0.0 % | 35.6 | 120.4 % | 14.7 % | 1.0 (12) |
| ANAB AnaptysBio Inc | 08/05 | +114 % | 81 7/22 | Stage 2 | C -10 | 3 of 9 | 1.8 | Biotechnology | – | — | — | Healthcare | 50.30 $ | +83.9 % | +97.9 % | +284.4 % | −18.6 % | +45.9 % | 96 | 42 | 5.8 % | 5.3 % | 0.38 | — | 0.0 | 7.6 | 136.2 | 401.6 | — | 27.4 | -135.5 % | 44.6 % | -11.5 % | -114.6 % | 6.8 % | 21.76 | 3.9 % | +157.0 % | 0.0 % | 0.0 % | 1.7 | 104.2 % | 35.6 % | 1.2 (12) |
| PVLA Palvella Therapeutics, Inc | 08/13 | +73 % | 27 3/22 | Stage 2 | D -45 | 3 of 9 | 2.0 | Biotechnology | – | — | — | Healthcare | 124.10 $ | +13.4 % | +46.3 % | +476.0 % | −9.9 % | +68.6 % | 95 | 42 | 7.0 % | 6.4 % | — | — | 0.0 | — | 8.4 | — | — | 0.0 | — | — | 0.0 % | -34.3 % | -16.6 % | 0.00 | — | -100.0 % | 0.0 % | 0.0 % | 14.3 | 96.4 % | 16.4 % | — |
| BOLD Boundless Bio, Inc. Common Stock | 08/04 | — | 81 7/22 | Stage 2 | E -59 | 1 of 9 | 0.1 | Biotechnology | – | — | — | Healthcare | 2.40 $ | +116.7 % | +9.0 % | +152.4 % | −10.0 % | +59.4 % | 95 | 42 | 4.8 % | 4.4 % | 0.40 | — | 0.0 | — | 0.7 | — | — | 0.0 | — | — | 0.0 % | -50.2 % | -22.8 % | 0.56 | — | — | 0.0 % | 0.0 % | -0.1 | 49.7 % | 0.2 % | — |
| SEPN Septerna, Inc. Common Stock | 08/10 | — | — | Stage 2 | C -4 | 4 of 9 | 0.0 | Biotechnology | – | — | — | Healthcare | 32.20 $ | +31.2 % | +17.9 % | +242.4 % | −9.1 % | +30.3 % | 94 | 50 | 7.5 % | 6.9 % | — | — | 107.5 | — | — | — | — | 0.0 | — | 100.0 % | -49.9 % | -9.3 % | -8.5 % | — | — | +4,174.5 % | 0.0 % | 0.0 % | 7.0 | 102.7 % | 11.7 % | — |
| MEC Mayville Engineering Co Inc | 08/04 | +51 % | 49 6/29 | Stage 2 | D -15 | 3 of 9 | 0.9 | Metal Fabrication | – | — | — | Industrials | 29.10 $ | +82.5 % | +96.1 % | +111.8 % | −3.3 % | -4.5 % | 94 | 1 | 5.2 % | 6.5 % | 1.22 | — | 22.1 | 1.6 | 4.1 | 61.2 | — | 37.1 | — | 10.7 % | -2.9 % | -6.8 % | -0.7 % | 0.10 | — | -6.0 % | 0.0 % | 0.0 % | 4.6 | 60.8 % | 5.0 % | — |
| TRVI Trevi Therapeutics Inc | 08/06 | +178 % | 55 5/22 | Stage 2 | D -47 | 3 of 9 | 2.6 | Biotechnology | – | — | — | Healthcare | 16.80 $ | +38.8 % | +43.6 % | +204.7 % | −0.9 % | +32.8 % | 93 | 42 | 6.1 % | 5.0 % | 1.00 | — | 0.0 | — | — | — | — | -4.9 | 0.0 % | — | 0.0 % | -33.6 % | -23.0 % | — | 95.8 % | — | 0.0 % | 0.0 % | 25.7 | 98.3 % | 11.2 % | 1.0 (8) |
| JBIO Jade Biosciences, Inc. | 08/12 | -21 % | 55 5/22 | Stage 2 | E -53 | 2 of 9 | 1.2 | Biotechnology | – | — | — | Healthcare | 19.70 $ | +42.4 % | +33.8 % | +121.9 % | −22.1 % | +122.4 % | 93 | 42 | 9.6 % | 9.1 % | — | — | 0.0 | — | 4.5 | — | — | 0.0 | — | — | 0.0 % | -89.2 % | -33.6 % | 0.00 | — | — | 0.0 % | 0.0 % | 18.0 | 84.8 % | 10.1 % | — |
| MRNA Moderna Inc | 08/07 | -16 % | 25 3/22 | Stage 2 | C -8 | 3 of 9 | 23.7 | Biotechnology | – | — | — | Healthcare | 59.50 $ | +106.8 % | +112.8 % | +135.4 % | −11.8 % | -23.3 % | 92 | 5 | 9.7 % | 7.0 % | 0.94 | — | 23.0 | 10.7 | 3.2 | — | — | 4.6 | -131.1 % | -69.9 % | -143.6 % | -36.6 % | -13.1 % | 0.18 | 64.5 % | -39.2 % | 0.0 % | 0.0 % | 6.9 | 79.0 % | 18.1 % | 1.9 (27) |
| RAPP Rapport Therapeutics, Inc. Common | 08/06 | — | 55 5/22 | Stage 2 | D -34 | 4 of 9 | 1.8 | Biotechnology | – | — | — | Healthcare | 40.20 $ | +28.1 % | +30.6 % | +267.7 % | −8.0 % | +45.6 % | 92 | 42 | 6.0 % | 6.1 % | 0.95 | — | 0.0 | 91.6 | 4.0 | — | — | 0.0 | — | 34.3 % | 0.0 % | -28.3 % | -19.1 % | 0.02 | — | — | 0.0 % | 0.0 % | 25.1 | 109.6 % | 7.5 % | — |
| GHM Graham Corporation | 08/04 | +251 % | — | Stage 2 | C +9 | 1 of 9 | 0.0 | Specialty Industrial Machinery | – | — | — | Industrials | 105.10 $ | +70.9 % | +69.7 % | +138.3 % | −1.0 % | +6.4 % | 91 | 50 | 6.2 % | 6.7 % | 1.01 | — | 58.8 | — | — | — | 3.26 | 59.6 | 1.3 % | 23.6 % | 5.1 % | 9.6 % | 3.4 % | — | 43.4 % | +16.9 % | 0.0 % | 0.0 % | 5.4 | 80.2 % | 4.6 % | 1.2 (5) |
| SATS EchoStar Corporation | 07/30 | +170 % | 84 8/24 | Stage 1 | D -45 | 4 of 9 | 28.2 | Telecom Services | Neutral | — | — | Communication Services | 92.00 $ | -4.4 % | -5.7 % | +298.7 % | −34.0 % | +41.7 % | 90 | 5 | 6.8 % | 7.3 % | 0.96 | — | 1.9 | 1.9 | 5.0 | — | 1.33 | 19.6 | 8.9 % | 27.1 % | -97.6 % | -112.3 % | 0.4 % | 5.20 | 13.6 % | -5.2 % | 0.0 % | 0.0 % | -0.9 | 112.2 % | 36.5 % | 1.6 (7) |
| ALKS Alkermes Plc | 08/04 | +15 % | 68 6/22 | Stage 2 | C 0 | 1 of 9 | 8.8 | Drug Manufacturers - Special | – | — | — | Healthcare | 51.70 $ | +71.8 % | +84.2 % | +72.4 % | −1.6 % | -5.0 % | 90 | 9 | 4.8 % | 4.2 % | 0.29 | 61.2 | 142.9 | 5.6 | 5.3 | 39.7 | 1.96 | 36.8 | -0.2 % | 87.5 % | 9.8 % | 9.4 % | 4.7 % | 0.90 | 41.1 % | -5.3 % | 0.0 % | 0.0 % | 4.9 | 110.5 % | 15.0 % | 1.4 (15) |
| SPIR Spire Global Inc | 08/12 | +124 % | 85 10/29 | Stage 2 | D -21 | 4 of 9 | 0.6 | Specialty Business Services | Sells AI | — | — | Industrials | 11.00 $ | +132.5 % | +114.7 % | +76.8 % | −38.3 % | +30.6 % | 90 | 42 | 9.1 % | 11.1 % | 2.52 | 10.3 | 0.0 | 9.3 | 7.3 | — | — | 9.9 | — | 42.3 % | 77.1 % | 101.2 % | -27.2 % | 0.13 | — | -35.2 % | 0.0 % | 0.0 % | -8.1 | 39.9 % | 12.3 % | — |
| KPTI Karyopharm Therapeutics Inc | 08/10 | -23 % | 94 9/22 | Stage 2 | D -25 | 4 of 9 | 0.2 | Biotechnology | Uses AI | — | — | Healthcare | 7.50 $ | +31.1 % | +35.0 % | +110.6 % | −13.9 % | +42.7 % | 89 | 42 | 7.7 % | 8.7 % | 0.81 | — | 0.0 | 1.4 | 12.1 | — | — | -1.9 | — | 13.5 % | -129.0 % | -891.1 % | -40.6 % | -0.87 | — | +0.6 % | 0.0 % | 0.0 % | -48.8 | 83.7 % | 24.8 % | — |
| CGON CG Oncology, Inc. Common stock | 08/14 | — | 68 6/22 | Stage 2 | C +2 | 4 of 9 | 6.5 | Biotechnology | – | — | — | Healthcare | 70.20 $ | +58.3 % | +83.7 % | +167.8 % | −3.5 % | +24.0 % | 88 | 42 | 6.2 % | 5.5 % | 0.22 | — | 0.0 | 1,269.0 | 5.9 | — | — | 0.0 | -6,130.1 % | -2,670.9 % | 0.0 % | -20.8 % | -14.4 % | 0.01 | 96.2 % | +254.7 % | 0.0 % | 0.0 % | 33.4 | 109.9 % | 12.2 % | 1.1 (10) |
| KYMR Kymera Therapeutics Inc | 08/10 | +109 % | 54 5/22 | Stage 2 | D -29 | 4 of 9 | 9.7 | Biotechnology | – | — | — | Healthcare | 111.10 $ | +26.3 % | +31.5 % | +115.8 % | −10.5 % | +6.3 % | 87 | 42 | 8.9 % | 6.0 % | 1.96 | — | 0.0 | 187.9 | 5.3 | — | — | -9.5 | -244.9 % | -549.8 % | 0.0 % | -27.1 % | -17.2 % | 0.05 | 92.3 % | -16.7 % | 0.0 % | 0.0 % | 14.7 | 117.6 % | 15.6 % | 1.2 (20) |
| AVBP ArriVent BioPharma, Inc. Common St | 08/10 | — | 55 5/22 | Stage 2 | D -26 | 2 of 9 | 1.5 | Biotechnology | – | — | — | Healthcare | 28.20 $ | +67.7 % | +54.2 % | +40.4 % | −2.6 % | +29.0 % | 87 | 42 | 6.0 % | 5.9 % | 1.30 | — | 0.0 | — | 4.9 | — | — | 0.0 | — | — | 0.0 % | -55.2 % | -34.7 % | 0.00 | — | — | 0.0 % | 0.0 % | 15.6 | 95.9 % | 17.9 % | — |
Price Chart
Quarterly Figures
No quarterly data available.
Frequently Asked Questions
Bonde's dollar breakdown (original Stockbee formula 'o−c ≥ 0.90'): the stock closes at least $0.90 below its opening price — sustained selling pressure across the whole trading day, measured in dollars. Minimum daily volume 100,000 shares, average volume (50 days) ≥ 100,000 as a liquidity filter. Opening price calculated from the prior close and the gap.
All scanners are recalculated daily across the entire stock universe — most recently on 21. July 2026. The data basis is fundamental data and SEC filings (10-K annual reports and 10-Q quarterly reports).
Currently, 115 stocks pass this scanner's criteria (as of 21. July 2026). The 25 strongest hits are shown.
Global filters: 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); fundamentally healthy names (Piotroski ≥ 5 or Funda Rating ≥ +10) are excluded.
This scanner deliberately hunts for red flags — a hit is a finding, not a recommendation: like a smoke detector that beeps so you look in time. A hit is also not a bankruptcy verdict; most companies save themselves (say, through a capital raise, which dilutes existing shareholders). Portfolio owners use the list as an early-warning system, bargain hunters as an anti-shopping list, experienced traders as a watch list — it is never a buy or short recommendation.
Related scanners
- Altman Z: Distress Zone
- Below the 50- & 200-SMA
- Beneish M-Score
- Downward Momentum
- Going Concern (Distress Proxy)
- Insolvency Radar: Cash Running Low
- Kathy Donnelly: Liquid Movers Down
- Mike Webster: Overextended (Webby RSI)
- Near 52-Week Low
- Pradeep Bonde: 4% Breakout Bearish
- Qullamaggie: Parabolic (Short-Watch)
- RS Weakness (≤10)
- Stage 4 (Downtrend)
- Stan Weinstein: Stage 4
- Stan Weinstein: Stage 4B-
- Thomas Insolvency Candidate
- Weakness Cluster
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.